This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Adjunctive pramlintide significantly delayed peak postprandial plasma glucose and reduced glucose excursions and incremental glucose area under the curve during closed-loop insulin delivery. Liraglutide also reduced glucose excursions and incremental glucose AUC, decreased prandial and total daily insulin doses by approximately 26-28%, and induced a mean weight loss of 3.2 kg over 3-4 weeks.
Why it matters
Improving post-meal blood sugar control without increasing insulin doses can reduce diabetes complications and improve quality of life. These adjunctive therapies offer a promising insulin-sparing approach to enhance closed-loop insulin delivery systems.
How the study worked
Two outpatient studies were conducted with young adults with type 1 diabetes using closed-loop insulin delivery. Subjects underwent 3-4 weeks of dose escalation of either pramlintide (60 μg/meal) or liraglutide (1.8 mg daily), followed by two 24-hour sessions comparing closed-loop alone versus closed-loop plus adjunctive therapy. Meals were standardized and unannounced during sessions to assess postprandial glucose control.
What this study cannot tell us
The sample sizes were small and limited to young adults with relatively well-controlled type 1 diabetes. The short duration (3-4 weeks) limits understanding of long-term effects and safety. Larger, longer-term studies are needed.
Read the original research
Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.
Diabetes care, 39(7), 1127-34
Citation
Sherr, Jennifer L; Patel, Neha S; Michaud, Camille I; Palau-Collazo, Miladys M; Van Name, Michelle A; Tamborlane, William V; Cengiz, Eda; Carria, Lori R; Tichy, Eileen M; Weinzimer, Stuart A. (2016). Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.. Diabetes care, 39(7), 1127-34. https://doi.org/10.2337/dc16-0089